Efficacy analysis of CDK4/6 inhibitors (CDKi) plus endocrine therapy (ET) treatment in hormone receptor-positive/HER2-negative (HR+/HER2-) advanced breast cancer (aBC): Biomarker analysis including chemoendocrine score (CES) by CDKi type in SOLTI-1801_CDK-PREDICT study

被引：0
|
作者：
Tolosa Ortega, Pablo
Pascual, Tomas
Hernando, Cristina
Servitja, Sonia
Fernandez-Abad, Maria
Braso-Maristany, Fara
Benitez Fuentes, Javier David
Lema, Laura
Parrilla Rubio, Lucia
Ruano, Yolanda
Maria Roncero, Ana
Sanchez-Bayona, Rodrigo
Alva Bianchi, Manuel
Villacampa, Guillermo
Cobos-Fernandez, Maria Angeles
del Rocio Moreno, Maria
Canes, Jordi
Salvador, Fernando
Prat, Aleix
Ciruelos, Eva M.
机构：
[1] Hosp 12 Octubre, Dept Med Oncol, Madrid, Spain
[2] Hosp Clin Barcelona, August Pi & Sunyer Biomed Res Inst IDIBAPS, Translat Genom & Targeted Therapeut Solid Tumors, Dept Med Oncol,SOLTI Breast Canc Cooperat Grp, Barcelona, Spain
[3] Hosp Clin Univ Valencia, Dept Med Oncol, Biomed Res Inst INCLIVA, Valencia, Spain
[4] Hosp Mar, Barcelona, Spain
[5] Ramon y Cajal Univ Hosp, Dept Med Oncol, Madrid, Spain
[6] Hosp Clin Barcelona, Dept Med Oncol, Barcelona, Spain
[7] August Pi & Sunyer Biomed Res Inst IDIBAPS, Barcelona, Spain
[8] Hosp Clin San Carlos, Dept Med Oncol, IdISSC, Madrid, Spain
[9] 12 Octubre Univ Hosp, Madrid, Spain
[10] Hosp Univ 12 Octubre, Dept Pathol, Madrid, Spain
[11] Hosp Univ 12 Octubre Res Inst, Mol Pathol Unit, Madrid, Spain
[12] SOLTI Canc Res Grp, Barcelona, Spain
[13] Univ Hosp 12 Octubre, Dept Med Oncol, Breast Canc Unit, GEICAM Spanish Breast Canc Grp, Madrid, Spain
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1065
引用
收藏
页数：1
相关论文
共 50 条
  • [41] Elderly patients with hormone receptor-positive HER2-negative metastatic breast cancer treated with CDK4/6 inhibitors in a multicentre cohort
    Pla, Helena
    Felip, Eudald
    Obadia, Veronica
    Pernas, Sonia
    Vinas, Gemma
    Margeli, Mireia
    Fort-Culillas, Roser
    Del Barco, Sonia
    Sabate, Nuria
    Fort, Eduard
    Lezcano, Clara
    Cirauqui, Beatriz
    Quiroga, Vanesa
    Stradella, Agostina
    Gil, Miguel Gil
    Esteve, Anna
    Recalde, Sabela
    CLINICAL & TRANSLATIONAL ONCOLOGY, 2024, 26 (07): : 1748 - 1758
  • [42] The Mutational Landscape of 1172 Patients with Hormone Receptor-Positive, HER2-negative Metastatic Breast Cancer Treated with CDK4/6 Inhibitors
    Shah, Ami N.
    Lim, Bora
    Mita, Monica M.
    Mauer, Elizabeth
    Layng, Kayla V.
    Chao, Calvin
    Brufsky, Adam M.
    CANCER RESEARCH, 2023, 83 (05)
  • [43] Peripheral blood lymphocyte counts predict clinical outcomes in patients with hormone receptor-positive HER2-negative advanced breast cancer treated with CDK4/6 inhibitors
    Vernieri, C.
    Zattarin, E.
    Mariani, L.
    Menichetti, A.
    Leporati, R.
    Ligorio, F.
    Fuca, G.
    Lobefaro, R.
    Griguolo, G.
    Sirico, M.
    Bernocchi, O.
    Marra, A.
    Agostinetto, E.
    Jacobs, F.
    Di Mauro, P.
    Curigliano, G.
    Pedersini, R.
    Losurdo, A.
    Generali, D.
    Dieci, M. V.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S641 - S642
  • [44] Mechanisms of Resistance to CDK4/6 Blockade in Advanced Hormone Receptor-positive, HER2-negative Breast Cancer and Emerging Therapeutic Opportunities
    Lloyd, Maxwell R.
    Spring, Laura M.
    Bardia, Aditya
    Wander, Seth A.
    CLINICAL CANCER RESEARCH, 2022, 28 (05) : 821 - 830
  • [45] Ribociclib plus letrozole vs placebo plus letrozole in postmenopausal women with hormone receptor-positive (HR+), HER2-negative (HER2-) advanced breast cancer (ABC) and a high disease burden
    Verma, S.
    Gil-Gil, M.
    Hegg, R.
    Wheatley-Price, P.
    Kattan, J.
    Bourgeois, H.
    Sutradhar, S.
    Miller, M.
    Campone, M.
    ANNALS OF ONCOLOGY, 2017, 28
  • [46] The association of hormone receptor expression level and clinical efficacy of CDK4/6 inhibitor in hormone receptor-positive, HER2-negative metastatic breast cancer
    Bao, Kelvin K. H.
    Wong, Carol H. Y.
    Yung, Jackie
    Tam, Venus
    Cheung, Ka Man
    Chan, Jeffrey C. H.
    Yiu, Harry H. Y.
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [47] Ribociclib plus endocrine therapy in hormone receptor-positive, HER2-negative advanced breast cancer: A pooled safety analysis
    Burris, H. A.
    Chan, A.
    Im, S-A
    Chia, S.
    Tripathy, D.
    Esteva, F. J.
    Campone, M.
    Bardia, A.
    Kong, O.
    Bao, W.
    Diaz-Padilla, I.
    Lorenc, K. Rodriguez
    Yardley, D. A.
    CANCER RESEARCH, 2019, 79 (04)
  • [48] Mutational signature analysis reveals patterns of genomic instability linked to resistance to endocrine therapy (ET) +/- CDK 4/6 inhibition (CDK4/6i) in estrogen receptor-positive/HER2-negative (ER+/HER2-) metastatic breast cancer (MBC)
    Marra, A.
    Gazzo, A.
    Gupta, A.
    Selenica, P.
    Da Silva, E. M.
    Pareja, F.
    Pei, X.
    Zhu, Y.
    Razavi, P.
    Safonov, A.
    Ferraro, E.
    Harris, R.
    Riaz, N.
    Reis-Filho, J. S.
    Chandarlapaty, S.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S632 - S632
  • [49] CDK4/6 inhibitor treatment for patients with hormone receptor-positive, HER2-negative, advanced or metastatic breast cancer: a US Food and Drug Administration pooled analysis
    Gao, Jennifer J.
    Cheng, Joyce
    Bloomquist, Erik
    Sanchez, Jacquelyn
    Wedam, Suparna B.
    Singh, Harpreet
    Amiri-Kordestani, Laleh
    Ibrahim, Amna
    Sridhara, Rajeshwari
    Goldberg, Kirsten B.
    Theoret, Marc R.
    Kluetz, Paul G.
    Blumenthal, Gideon M.
    Pazdur, Richard
    Beaver, Julia A.
    Prowell, Tatiana M.
    LANCET ONCOLOGY, 2020, 21 (02): : 250 - 260
  • [50] Bosutinib and exemestane (EXE) versus EXE alone in postmenopausal (postm) women with hormone receptor-positive (HR+) HER2-negative (HER2-) advanced breast cancer (ABC).
    Moy, B.
    Lebrun, F.
    Bellet, M.
    Chow, L.
    Lang, I.
    Xu, B.
    Badwe, R. A.
    Hershman, D. L.
    Leip, E.
    Bardy-Bouxin, N.
    Duvillie, L.
    Neven, P.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
12345